NCT06589219View on ClinicalTrials.gov

Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Pulmonary Fibroses, Idiopathic
Interventions
DRUG

CMR316

CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort

DRUG

Placebo

Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration

Trial Locations (1)

30625

RECRUITING

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Hanover

All Listed Sponsors
lead

Calibr, a division of Scripps Research

OTHER